Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYHA1813 + paclitaxel
- Development stage
- Phase 2
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
SYHA1813 + paclitaxel is an experimental combination therapy investigated for the treatment of malignant tumors. **SYHA1813** is a novel, investigational, small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4), developed primarily for antitumor activity in cancers characterized by dysregulated FGFR4 signaling. **Paclitaxel** is an approved antineoplastic agent widely utilized in multiple cancer types including breast, ovarian, and lung cancer. Paclitaxel acts as a microtubule stabilizer, disrupting mitosis and inducing apoptosis by binding to β-tubulin and preventing microtubule depolymerization[1][2][4][8]. The combination is under clinical investigation for possible synergistic or additive effects in tumor inhibition.
- Brand names
- Abraxane
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)VEGFR (VEGFR family)FGFR4 (Fibroblast growth factor receptor 4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SYHA1813 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYHA1813 + paclitaxel.